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ObituaryPaul J. Leibson 1952–2007The scientific community is deeply
saddened by the loss of Paul J. Leib-
son, M.D., Ph.D., who passed away
last August at the age of 55 after
a very short battle with a rare form of
cancer. For more than 20 years, Paul
has been an international leader in
the area of NK cell biology and lym-
phocyte signaling. Through his stud-
ies, we have come to appreciate
more fully the molecular mechanisms
by which distinct activating and in-
hibitory receptors regulate the devel-
opment of cell-mediated killing and
cytokine secretion by this unique lym-
phocyte subpopulation.
Paul was born to Ruth and Benton
Leibson and grew up in the greater
Chicago area with his brothers Marc
and David. Paul attended the Univer-
sity of Illinois Urbana-Champaign and
graduated magna cum laude with
a B.S. in 1974. He subsequently at-
tended the University of Chicago as
an M.D., Ph.D. candidate, and there
he trained with Dr. Hans Schreiber in
immunology. After obtaining his M.D.,
Ph.D. degree in 1981 with honors,
Paul pursued a pediatric internship at
the University of Colorado Health Sci-
ence Center in Denver, CO, and in
1984 began a fellowship in allergy
and immunology with Anthony Hay-
ward at the National Jewish Hospital
and Research Center in Denver, CO.
In 1986, Paul joined the Department
of Immunology at the Mayo Clinic Ro-
chester, MN, and began his indepen-
dent research career. During the next
21 years, he would rise through the
ranks to Professor of Immunology.
During his time at Mayo, Paul also
committed himself to teaching and
was Dean of the Mayo Graduate
School for 5 years. He was recognized
as ‘‘Teacher of the Year’’ by the immu-
nology graduate students, was aMayo
Distinguished Educator, and earned
the Rose M. and Morris Eisenberg
Professorship for his dedication to
research and teaching. As an enthusi-
astic teacher and clear speaker, Paul
was a great motivator of young scien-
tists. He trained several medical fel-lows, postdoctoral fellows, and grad-
uate students, many of whom have
since succeeded as productive inde-
pendent investigators.
A long-standing interest of Paul’s
was to understand how NK cells kill.
Starting in the late 1980s, he began ex-
ploring the effector molecules involved
in the process, by investigating the
roles of TNF, lymphotoxin, and Fas li-
gand, as well as the cellular machinery
involved in degranulation of cytotoxic
cell. Over his career, Paul contributed
to the characterization of numerous
signaling pathways in NK cells that
could both positively and negatively
regulate cell-mediated killing. Even
prior to the identification of the activat-
ing and inhibitory receptors that con-
trol NK cell responses, his own work
laid some of the foundations for subse-
quent research on signaling for acti-
vation and inhibition in NK cells. He
established that NK cell cytotoxicity
could be triggered by different recep-
tors through distinct signaling path-
ways. Early on, he showed that NK
cell contact with MHC class I-positive,
resistant target cells resulted in a block
of intracellular release of free Ca2+. In-
hibition upstream of Ca2+ flux implied
that negative signaling had to occur
at a very proximal step, within aminute
or so. Much of the subsequent work in
the field of NK cell regulation has been
guided by basic principles laid out in
Paul’s pioneering work.
Paul finds the ‘‘Mother of all Morels’’ in
the spring of 2006.Immunity 2In the mid-1970s to early 1980s,
a lymphocyte subpopulation that could
kill certain malignant and virus-in-
fected cells without prior sensitization
or MHC restriction was described. An-
tiviral activity by these cells provided
a major early immune defense against
viruses in vivo. The early work on NK
cells, including Paul’s work with An-
thony Hayward, required the isolation
ofmononuclear cells and either enrich-
ment or depletion techniques to isolate
or remove NK cell populations from
the mononuclear cell preparations. Al-
though these studies were useful in
defining the innate immune character-
istics of this new subpopulation of
cells, more in-depth biochemical char-
acterization of the signaling pathways
activated in response to either tumor
cells or virus-infected cells was not
possible. Unlike the availability of hu-
man T cell lines and reagents for the T
cell receptor (TCR), no human trans-
formed NK cell line was available, and
knowledge on NK cell-activating re-
ceptors was limited, aside from the
FcgRIII receptor (CD16). Although
Paulwas convinced that shared signal-
ing pathways might be utilized during
the activation of T cells and NK cells,
he realized that in order to understand
the molecular mechanisms regulating
NK cell-mediated cytotoxicity and to
perform the kind of biochemical exper-
iments that he was interested in, he
needed to obtain larger and homoge-
nous populations of NK cells, prefera-
bly nontransformed. Paul succeeded
in developing a protocol to isolate and
grow clonal populations of NK cells in
sufficient quantity for his proposed
experiments. This represented a large
step forward in his ability to gain a
more complete understanding of the
signaling pathways activated during
the development of cellular cytotox-
icity. In fact, NK cell clones would
become the mainstay of Paul’s re-
search and would afford him and other
NK cell researchers the opportunity to
dissect themechanisms bywhich acti-
vating and inhibitory receptors function
on NK cells.7, October 2007 ª2007 Elsevier Inc. 531
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Paul’s lab quickly demonstrated the
requirement for the generation of sec-
ond messengers (IP3 and cAMP), as
well as activation of the tyrosine kinase
Lck, which is a proximal component in
TCR signaling, and numerous other
signaling molecules (e.g., Syk, PLCg,
PI3-K, and Vav) in the regulation of
natural cytotoxicity and FcR-mediated
(i.e., antibody-dependent) cellular cy-
totoxicity. Paul realized that a method
of expressing wild-type and domi-
nant-negative proteins in NK cell
clones was needed in order to further
our understanding of the signaling
mechanisms involved in regulating
NK cells. Unfortunately, unlike the suc-
cess T cell biologists were having with
transformed T cell lines such as Jurkat,
cloned primary human NK cells were
virtually resistant to transfection of
plasmid DNA. This shortcoming was
predominantly overcome by the adop-
tion and development of recombinant
vaccinia-virus technology into Paul’s
lab during the 1990s. This approach
launched more in-depth signaling
studies because virtually any signaling
protein could be evaluated for its con-
tribution to NK cell signaling through
the expression of wild-type and domi-
nant-negative proteins. As times for
genetic manipulation changed from
overexpression studies to RNA inter-
ference, Paul met the challenge head
on and quickly worked out methods
for transfection of small-interfering
RNAs into human NK cell clones.
Once inhibitory receptors for HLA
class I were identified in 1995, Paul
was among the first to provide a mo-
lecular basis for the balance between
the positive and negative signaling532 Immunity 27, October 2007 ª2007 Epathways. In elegant studies pub-
lished in Immunity in 1996, he defined
a link between Src-family-kinase-
mediated phosphorylation of the inhib-
itory receptor and the subsequent ac-
tion of SHP-1 on the ITAM-dependent
Fc receptor activation pathway. More
recently, Paul contributed substan-
tially to our understanding of signaling
by the human NKG2D receptor com-
plex, which contributes to natural cy-
totoxicity by recruiting Grb2 and Vav1.
Paul’s contributions continue to move
the field forward, as attested by his first
posthumous paper, published in the
September 15 issue of the Journal of
Immunology, in which he describes
that defects in the SNARE protein syn-
taxin 11 in familial hemophagocytic
lymphohistiocytosis 4 patients impair
cytolytic function inNKcells andTcells.
Beside his love of science, Paul en-
joyed spending time with family and
friends, traveling, eating food, drinking
wine, and foraging the forests of
southern Minnesota in the spring for
the elusive morel mushroom, which in-
evitably resulted in eating more food
and drinking more wine. Paul was
also one of the most positive and opti-
mistic individuals we have ever met,
not to mention humorous. Regardless
of the situation, Paul maintained a pos-
itive outlook and would always make
the best of whatever life tossed his
way. Despite his prognosis, Paul con-
tinued toguidehis students andpursue
science. His dedication to hiswork and
optimism are best exemplified by the
fact that days before his surgery in
June 2007, Paul was working on a re-
vised version of his NIH grant that he
had had for the past 19 years. He sub-
mitted it the day before surgery.lsevier Inc.Paul’s passion for science con-
stantly kept him at the forefront of NK
cell biology and signaling. To those
working on similar questions, he was
a generous and supportive colleague,
more interested in advancing the field
than in competing toward short-term
goals. Discussions with him were
open, informative, and enjoyable. His
qualities as a kind and thoughtful per-
son always came through, no matter
what the scientific argument might
have been. He was a wonderful host,
known to prepare dinners for appre-
ciative visitors and share special wines
from his own collection. A regret
shared by many of us is to have not
taken more time to know him better
on a personal level. We have all en-
joyed Paul’s work and benefited from
his important contributions to science.
Although his life ended too soon,
Paul’s excitement for science will live
on with his trainees and colleagues
who knew him well. His legacy will
surely stand the test of time.
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